SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Clown-Free Zone... sorry, no clowns allowed
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: reaper who wrote (168533)5/28/2002 9:14:44 PM
From: EepOpp   of 436258
 
Even if generic drugmakers are successful in pleading their case in New York, they risk incurring significant damages if they launch copycats before the conclusion of an appeals case, which is likely to be brought by AstraZeneca if it loses.

A generic drugmaker that launches a copycat drug but then loses an appeals court decision can face expensive lawsuits from the original manufacturer of the medicine -- especially if the treatment is as lucrative as Prilosec.

biz.yahoo.com

___________________________________________

reaper,

i was wondering if you have followed generic companies enough to know whether or not they're likely to start selling a drug even if they know that an appeal is probable.

thanks.

EO
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News